scispace - formally typeset
D

David Cameron

Researcher at University of Oslo

Publications -  1765
Citations -  141776

David Cameron is an academic researcher from University of Oslo. The author has contributed to research in topics: Large Hadron Collider & Breast cancer. The author has an hindex of 154, co-authored 1586 publications receiving 126067 citations. Previous affiliations of David Cameron include Universidade Nova de Lisboa & Cameron International.

Papers
More filters
Journal ArticleDOI

Search for the Standard Model Higgs boson decaying into bb¯ produced in association with top quarks decaying hadronically in pp collisions at √s = 8 TeV with the ATLAS detector

Georges Aad, +2826 more
- 27 May 2016 - 
TL;DR: In this paper, a search for Higgs boson production in association with a pair of top quarks (t (t) over barH) is performed, where the Higgs Boson decays to b (b) over the bar, and both top Quarks decay hadronically.
Journal ArticleDOI

A measurement of the ratio of the production cross sections for W and Z bosons in association with jets with the ATLAS detector

Georges Aad, +2885 more
- 02 Dec 2014 - 
TL;DR: In this article, the production cross sections for W and Z bosons in association with jets have been measured in proton-proton collisions at root s = 7 TeV with the ATLAS experiment at the Large Hadron Collider.
Journal ArticleDOI

Cancer survivorship: Reproductive health outcomes should be included in standard toxicity assessments.

Richard A. Anderson, +7 more
- 01 Feb 2021 - 
TL;DR: The effects of cancer treatment on reproductive function in both sexes may lead to loss of fertility, sexual desire and function, and hormone deficiency, which results in additional long-term morbidity in more than a third of patients as mentioned in this paper.
Proceedings ArticleDOI

Outcomes of Women Who Were Premenopausal at Diagnosis of Early Stage Breast Cancer in the NCIC CTG MA17 Trial.

Paul E. Goss, +13 more
- 15 Dec 2009 - 
TL;DR: A subset of women in the MA17 trial who were premenopausal at initial diagnosis and in whom subsequent menopause, prior to randomization, may have influenced their outcome on extended adjuvant letrozole are reported on.
Journal ArticleDOI

Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab

Thomas E. Delea, +8 more
- 01 Oct 2012 - 
TL;DR: When compared against capecitabine alone, the addition of lapatinib has a cost-effectiveness ratio exceeding the threshold normally used by NICE, and is approximately equally likely to be cost-effective in probabilistic sensitivity analyses over a wide range of threshold values.